NEW YORK, May 2 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO) announced today that it has appointed Rajiv Garg as it Chief Financial Officer.
Pulmo BioTech Chief Executive Officer Garry McCann said that he was very pleased that Rajiv had agreed to join the company and that Rajiv's experience and financial acumen would be of great benefit to the company as it moved towards completion of its Phase I Human Trials and then into Phase II.
Rajiv has twenty one years of extensive experience in the investment banking and finance industry covering financial control, evaluation of businesses, regulatory liaison and development of macro/micro risk management systems.
Rajiv was educated at Westminster College in London, UK and the University of Delhi in India. He has an Honours Degree in Commerce and is a Member of the Institute of Chartered Accountants, a Member of the Securities and Futures Authority and a Member of the Global Association of Risk Professionals.
About Pulmo BioTech Inc.
Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Pulmo BioTech's mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.
About PulmoScience Inc.
PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind
The company was conceived within the Montreal Heart Institute "MHI" (a
world renowned hospital and educational f
|SOURCE Pulmo BioTech Inc.|
Copyright©2008 PR Newswire.
All rights reserved